ClearPoint Neuro, Inc.·4

May 21, 4:30 PM ET

Girin Pascal E R 4

Research Summary

AI-generated summary

Updated

ClearPoint Neuro (CLPT) Director Girin Receives 12,417 Shares

What Happened
Girin Pascal E R, a director of ClearPoint Neuro, had 12,417 restricted stock units (RSUs) vest and convert into 12,417 shares of CLPT common stock on May 19, 2026. The Form 4 records an acquisition by conversion (transaction code M) of 12,417 shares and a matching disposition entry of 12,417 shares; no per-share price or total dollar value is reported in the filing. This was a scheduled RSU settlement (an award vesting), not an open-market buy or a voluntary sale.

Key Details

  • Transaction date: 2026-05-19; Form 4 filed 2026-05-21 (timely filing).
  • Transaction type/code: Exercise/conversion of derivative (M) — settlement of RSUs into common stock.
  • Shares acquired: 12,417; shares disposed: 12,417 (both reported; no price reported).
  • Shares owned after transaction: not provided in the supplied data.
  • Footnote: F1 confirms these were 12,417 RSUs granted 2025-05-22 that vested on the earlier of the first anniversary or the day before the 2026 annual meeting; the filing states this transaction represents settlement of those RSUs.
  • The filing does not disclose a cash amount or explicit reason for the matching disposition entry (e.g., tax withholding or immediate sale is not specified).

Context
RSU vesting converts a contingent award into actual shares; this is a standard compensation event rather than a directional buy or sell signal. The matching disposition line is recorded but not explained in the filing — such dispositions sometimes reflect withholding to cover taxes or other administrative transfers, but the Form 4 here does not state the cause.